DEBORAH MOORE: Open Payments
NPI 1942353180 · SANTA BARBARA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,909 in 86 payments from 12 companies in 2025. Trend: 2023 $1,794 · 2024 $1,309 · 2025 $1,909
Food & beverage: $1,909
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $527 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $359 |
| Vanda Pharmaceuticals Inc. | 6 | $206 |
| Axsome Therapeutics, Inc. | 10 | $198 |
| Otsuka America Pharmaceutical, Inc. | 8 | $172 |
| Gilead Sciences, Inc. | 1 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $101 |
| Alkermes, Inc. | 3 | $70 |
| Teva Pharmaceuticals USA, Inc. | 2 | $53 |
| Almatica Pharma LLC | 2 | $49 |
Products named: VRAYLAR, CAPLYTA, FANAPT, REXULTI, Auvelity, Yeztugo, TRINTELLIX, ARISTADA.
Industry payments across CA — which companies pay providers there.
